BR102020016437B1 - Imunoglobulinas equinas anticoronavírus, anti-sars-cov-2 e moléculas delas derivadas e processo de produção das mesmas - Google Patents
Imunoglobulinas equinas anticoronavírus, anti-sars-cov-2 e moléculas delas derivadas e processo de produção das mesmas Download PDFInfo
- Publication number
- BR102020016437B1 BR102020016437B1 BR102020016437-6A BR102020016437A BR102020016437B1 BR 102020016437 B1 BR102020016437 B1 BR 102020016437B1 BR 102020016437 A BR102020016437 A BR 102020016437A BR 102020016437 B1 BR102020016437 B1 BR 102020016437B1
- Authority
- BR
- Brazil
- Prior art keywords
- sars
- cov
- solution
- equine
- production
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 45
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 38
- 241000283073 Equus caballus Species 0.000 title claims abstract description 37
- 230000008569 process Effects 0.000 title claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 26
- 229940072221 immunoglobulins Drugs 0.000 title claims description 12
- 238000001914 filtration Methods 0.000 claims abstract description 37
- 241000283086 Equidae Species 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 230000000521 hyperimmunizing effect Effects 0.000 claims abstract description 17
- 230000003053 immunization Effects 0.000 claims abstract description 13
- 239000012141 concentrate Substances 0.000 claims abstract description 12
- 239000012634 fragment Substances 0.000 claims abstract description 12
- 238000002649 immunization Methods 0.000 claims abstract description 12
- 230000001954 sterilising effect Effects 0.000 claims abstract description 9
- 239000002245 particle Substances 0.000 claims abstract description 8
- 238000000746 purification Methods 0.000 claims abstract description 8
- 238000004806 packaging method and process Methods 0.000 claims abstract description 7
- 230000003612 virological effect Effects 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 44
- 210000002966 serum Anatomy 0.000 claims description 43
- 239000012895 dilution Substances 0.000 claims description 30
- 238000010790 dilution Methods 0.000 claims description 30
- 239000000427 antigen Substances 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 10
- 238000000502 dialysis Methods 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 9
- 238000011049 filling Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 229940096437 Protein S Drugs 0.000 claims description 8
- 229910001220 stainless steel Inorganic materials 0.000 claims description 8
- 239000010935 stainless steel Substances 0.000 claims description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 7
- 238000003908 quality control method Methods 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 238000012546 transfer Methods 0.000 claims description 7
- 238000013019 agitation Methods 0.000 claims description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 6
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 6
- 230000000740 bleeding effect Effects 0.000 claims description 6
- 210000003743 erythrocyte Anatomy 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 208000025721 COVID-19 Diseases 0.000 claims description 5
- 102000029301 Protein S Human genes 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 4
- 102000057297 Pepsin A Human genes 0.000 claims description 3
- 108090000284 Pepsin A Proteins 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 239000013642 negative control Substances 0.000 claims description 3
- 229940111202 pepsin Drugs 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 108010066124 Protein S Proteins 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 2
- 238000004500 asepsis Methods 0.000 claims description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 claims description 2
- 229910001626 barium chloride Inorganic materials 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 229910001679 gibbsite Inorganic materials 0.000 claims description 2
- 230000005847 immunogenicity Effects 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 230000001175 peptic effect Effects 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- VZWGHDYJGOMEKT-UHFFFAOYSA-J sodium pyrophosphate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O VZWGHDYJGOMEKT-UHFFFAOYSA-J 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102100031673 Corneodesmosin Human genes 0.000 claims 1
- 101710139375 Corneodesmosin Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101000674278 Homo sapiens Serine-tRNA ligase, cytoplasmic Proteins 0.000 claims 1
- 101000674040 Homo sapiens Serine-tRNA ligase, mitochondrial Proteins 0.000 claims 1
- 102100040516 Serine-tRNA ligase, cytoplasmic Human genes 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 241001678559 COVID-19 virus Species 0.000 abstract description 13
- 241000711573 Coronaviridae Species 0.000 abstract description 12
- 102000006395 Globulins Human genes 0.000 abstract description 9
- 108010044091 Globulins Proteins 0.000 abstract description 9
- 238000005516 engineering process Methods 0.000 abstract description 3
- 108020004511 Recombinant DNA Proteins 0.000 abstract description 2
- 239000013020 final formulation Substances 0.000 abstract description 2
- 238000010647 peptide synthesis reaction Methods 0.000 abstract description 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 14
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 7
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 description 6
- 239000003708 ampul Substances 0.000 description 5
- 101710172711 Structural protein Proteins 0.000 description 4
- 238000011194 good manufacturing practice Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002906 microbiologic effect Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 241000315672 SARS coronavirus Species 0.000 description 3
- 241000270295 Serpentes Species 0.000 description 3
- 230000010530 Virus Neutralization Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000005352 clarification Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011046 pyrogen test Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 229940043517 specific immunoglobulins Drugs 0.000 description 3
- 231100000611 venom Toxicity 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000256844 Apis mellifera Species 0.000 description 2
- 241000701931 Canine parvovirus Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000271532 Crotalus Species 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 101710114810 Glycoprotein Proteins 0.000 description 2
- 101000619564 Homo sapiens Putative testis-specific prion protein Proteins 0.000 description 2
- 241000711450 Infectious bronchitis virus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101800001255 Putative 2'-O-methyl transferase Proteins 0.000 description 2
- 102100022208 Putative testis-specific prion protein Human genes 0.000 description 2
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 2
- 101710167605 Spike glycoprotein Proteins 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 101800000578 Uridylate-specific endoribonuclease Proteins 0.000 description 2
- 101800001927 Uridylate-specific endoribonuclease nsp15 Proteins 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000005429 filling process Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229910052573 porcelain Inorganic materials 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000005297 pyrex Substances 0.000 description 2
- 238000009517 secondary packaging Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000271506 Bothrops Species 0.000 description 1
- 241000907159 Bothrops alternatus Species 0.000 description 1
- 241000271517 Bothrops jararaca Species 0.000 description 1
- 241000711506 Canine coronavirus Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012369 In process control Methods 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 241000272038 Micrurus Species 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 241000701370 Plasmavirus Species 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000239273 Tityus Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000002096 anti-tetanic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 208000018747 cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010965 in-process control Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000000659 thermocoagulation Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102020016437-6A BR102020016437B1 (pt) | 2020-08-12 | 2020-08-12 | Imunoglobulinas equinas anticoronavírus, anti-sars-cov-2 e moléculas delas derivadas e processo de produção das mesmas |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102020016437-6A BR102020016437B1 (pt) | 2020-08-12 | 2020-08-12 | Imunoglobulinas equinas anticoronavírus, anti-sars-cov-2 e moléculas delas derivadas e processo de produção das mesmas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR102020016437A2 BR102020016437A2 (enrdf_load_stackoverflow) | 2021-11-16 |
| BR102020016437B1 true BR102020016437B1 (pt) | 2022-09-27 |
Family
ID=83897883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR102020016437-6A BR102020016437B1 (pt) | 2020-08-12 | 2020-08-12 | Imunoglobulinas equinas anticoronavírus, anti-sars-cov-2 e moléculas delas derivadas e processo de produção das mesmas |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BR102020016437B1 (enrdf_load_stackoverflow) |
-
2020
- 2020-08-12 BR BR102020016437-6A patent/BR102020016437B1/pt active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| BR102020016437A2 (enrdf_load_stackoverflow) | 2021-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200316192A1 (en) | Methods Of Vaccine Administration | |
| Krakowka et al. | Serologic response to canine distemper viral antigens in gnotobiotic dogs infected with canine distemper virus | |
| CN111471103A (zh) | 一种新冠病毒（2019-nCOV）的异源抗体及其制备方法 | |
| RU2710239C1 (ru) | Способ получения антигена или антигенов для производства противогриппозной вакцины и вакцина на его основе | |
| CN111658768A (zh) | 一种非洲猪瘟的多组分亚单位疫苗及其制备方法和应用 | |
| Barteling | Modern inactivated foot-and-mouth disease (FMD) vaccines: historical background and key elements in production and use | |
| US7794720B2 (en) | Isolated plasma and method for hyperimmunisation and plasma collection | |
| JPS63264532A (ja) | インフルエンザワクチン | |
| AU2021206905A1 (en) | Methods of vaccine administration | |
| CN113304257A (zh) | 一种双佐剂新型冠状病毒灭活疫苗的制备方法及应用 | |
| RU2754398C1 (ru) | Способ получения четырехвалентной вакцины для профилактики гриппа | |
| RU2584594C1 (ru) | Вакцина гриппозная инактивированная расщепленная и способ ее получения | |
| RU2451745C2 (ru) | ШТАММ А 2045/КИРГИЗИЯ/2007 ВИРУСА ЯЩУРА Aphtae epizooticae ТИПА А ДЛЯ КОНТРОЛЯ АНТИГЕННОЙ И ИММУНОГЕННОЙ АКТИВНОСТИ ПРОТИВОЯЩУРНЫХ ВАКЦИН И ДЛЯ ИЗГОТОВЛЕНИЯ БИОПРЕПАРАТОВ ДЛЯ ДИАГНОСТИКИ И СПЕЦИФИЧЕСКОЙ ПРОФИЛАКТИКИ ЯЩУРА ТИПА А | |
| JPH09110719A (ja) | 実質的には非宿主アルブミンを含有しないアジユバント化ワクチン | |
| BR102020016437B1 (pt) | Imunoglobulinas equinas anticoronavírus, anti-sars-cov-2 e moléculas delas derivadas e processo de produção das mesmas | |
| CN107304230A (zh) | 一种抗犬细小病毒精制抗体及其制备方法 | |
| WO2024255026A1 (zh) | 牛结节性皮肤病病毒阳性血清及其制备方法和应用 | |
| WO2022224271A1 (en) | Polyclonal antibodies against sars-cov-2 and implementations thereof | |
| CN1563088B (zh) | 一种抗流行性感冒特异性复合IgY及其制剂 | |
| RU2735782C1 (ru) | Способ получения стандартного образца содержания антител IgG человека к вирусу клещевого энцефалита | |
| RU2184567C1 (ru) | Штамм feline calicivirus, используемый для контроля иммуногенной активности вакцин, изготовления специфических лечебно-профилактических и диагностических биопрепаратов | |
| CN111269927A (zh) | 一种鸭圆环病毒的复合疫苗及卵黄抗体制备方法 | |
| RU2348690C2 (ru) | Штамм "амурский" № 1987 вируса ящура типа азия-1 для контроля антигенной и иммуногенной активности вакцин и для изготовления биопрепаратов для диагностики и специфической профилактики ящура типа азия-1 | |
| RU2297452C2 (ru) | Штамм азия-1/таджикистан/2004(1960) вируса ящура типа азия-1 для изготовления диагностических и/или вакцинных препаратов | |
| WO2002007760A2 (en) | Therapeutic agent against aids comprising anti hiv goat antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B150 | Others concerning applications: publication cancelled [chapter 15.30 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 15.21 NA RPI NO 2596 DE 06/10/2020 POR TER SIDO INDEVIDA. |
|
| B25A | Requested transfer of rights approved |
Owner name: INSTITUTO VITAL BRAZIL SA (BR/RJ) ; UNIVERSIDADE FEDERAL DO RIO DE JANEIRO (BR/RJ) ; ADILSON ANTONIO DA SILVA STOLET (BR/MG) ; MARCELO ABRAHAO STRAUCH (BR/RJ) |
|
| B25A | Requested transfer of rights approved |
Owner name: INSTITUTO VITAL BRAZIL SA (BR/RJ) ; UNIVERSIDADE FEDERAL DO RIO DE JANEIRO (BR/RJ) ; MARCELO ABRAHAO STRAUCH (BR/RJ) |
|
| B25A | Requested transfer of rights approved |
Owner name: INSTITUTO VITAL BRAZIL SA (BR/RJ) ; UNIVERSIDADE FEDERAL DO RIO DE JANEIRO (BR/RJ) |
|
| B03B | Publication of an application: publication anticipated [chapter 3.2 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/08/2020, OBSERVADAS AS CONDICOES LEGAIS |